` BVAXF (Biovaxys Technology Corp) vs S&P 500 Comparison - Alpha Spread

BVAXF
vs
S&P 500

Over the past 12 months, BVAXF has underperformed S&P 500, delivering a return of -41% compared to the S&P 500's 9% growth.

Stocks Performance
BVAXF vs S&P 500

Loading
BVAXF
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
BVAXF vs S&P 500

Loading
BVAXF
S&P 500
Difference
www.alphaspread.com

Performance By Year
BVAXF vs S&P 500

Loading
BVAXF
S&P 500
Add Stock

Competitors Performance
Biovaxys Technology Corp vs Peers

S&P 500
BVAXF
AMGN
ALNY
ARGX
603259
Add Stock

Biovaxys Technology Corp
Glance View

Market Cap
6.5m USD
Industry
N/A

BioVaxys Technology Corp. is a clinical stage biotechnology company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-11-21. The firm is focused on developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is using its haptenized antigen technology platforms to develop vaccines to treat viral infections, such as SARS-CoV-2, human papillomavirus (HPV) and cancers, such as late-stage ovarian cancer, cervical cancer and melanoma. Its product portfolio includes BVX-0320, BVX-0121, BVX-0204, BVX-0918A, BVX-0918C, CoviDTH and Papilocare. BVX-0320 is an investigational new drug (IND)-stage vaccine candidate for SARS-CoV-2. The vaccine is the recombinant S1 subunit of the spike protein of SARS-CoV-2 that has been modified with a chemical called hapten, specifically, dinitrophenyl (DNP). Its CoviDTH is a disposable, diagnostic tool to identify a T-cell immune response to the presence of SARS-CoV-2. BVX-0918A is a haptenized tumor cell vaccine for ovarian cancer.

BVAXF Intrinsic Value
0.0004 USD
Overvaluation 99%
Intrinsic Value
Price
B
Back to Top